NCT02389933No Longer Available不适用
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia (ALL)NCT04559555Novartis Pharmaceuticals
No Longer Available
不适用
Nilotinib, for Patients With CML-CP or CML-APChronic Myelogenous Leukemia (CML)NCT04518644Novartis Pharmaceuticals
Available
不适用
Managed Access Programs for ETB115, EltrombopagThrombocytopeniaNCT04837703Novartis Pharmaceuticals
No Longer Available
不适用
177Lu-PSMA-617 Managed Access Program for mCRPC PatientsMetastatic Castration-resistant Prostate Cancer (mCRPC)NCT04825652Advanced Accelerator Applications
Approved For Marketing
不适用
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USASmall Cell Lung CancerNCT04291937Jazz Pharmaceuticals